BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)

DOI: 10.1080/2162402X.2017.1372080

Keywords: Immunotherapy, Butyrophilin 3 A, BTN3A, CD277, Pancreatic Ductal Adenocarcinoma

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text